Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric long-term extension study of ustekinumab across ulcerative colitis, Crohn's disease, and juvenile psoriatic arthritis
2022-501067-40-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 3, open-label trial of ustekinumab in autoimmune colitis, Crohn's disease and juvenile psoriatic arthritis (JPsA) (3 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Adverse events and serious adverse events, Clinical laboratory assessments and 3 more. Planned start Mar 2023; status: authorised.
02
Drugs
ustekinumab
03
Conditions
autoimmune colitisCrohn's diseasejuvenile psoriatic arthritis (JPsA)
Beyond the preview
Go deeper on 2022-501067-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501067-40-00.